| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Institutes of Reproductive Medicine (M.Z., M.B., B.K., J.G., S.v.E., E.N.), Clinical Chemistry and Laboratory Medicine (A.v.E.), and Arteriosclerosis Research (A.v.E.), University of Münster, D-48129 Münster, Germany
Address all correspondence and requests for reprints to: Prof. Dr. E. Nieschlag, Institute of Reproductive Medicine, University of Munster, Domagkstrasse 11, D-48129 Münster, Germany. E-mail: nieschl{at}uni-muenster.de
Abstract
Genomic effects of T are exerted via the AR. The length of the polymorphic CAG repeat sequence in the AR gene is inversely correlated with the transcriptional regulation of target genes by T. In 110 healthy men (20–50 yr), we investigated the interactions among this polymorphism, serum levels of sex hormones, cardiovascular risk factors, and flow-mediated and nitrate-induced vasodilatation of the brachial artery. The number of CAG repeat had no significant correlations with serum concentrations of total or free T. Stepwise multiple regression analysis revealed positive correlations of the number of CAG repeat with serum levels of high density lipoprotein cholesterol (partial r = 0.44; P < 0.001) and flow-mediated vasodilatation (partial r = 0.37; P < 0.001). The association of CAG repeat with high density lipoprotein (HDL) cholesterol was independent of body fat content and serum levels of free T, which both had significant negative correlations with HDL cholesterol. The association of CAG repeat with flow-mediated vasodilatation was independent of cigarette smoking and serum levels of free T and low density lipoprotein cholesterol, which also were correlated with flow-mediated vasodilatation. We conclude that a low number of CAG repeat in the AR gene implies a greater chance for low levels of HDL cholesterol and reduced endothelial response to ischemia, which are both important risk factors for coronary heart disease.
LITTLE IS KNOWN about the role of T in atherosclerosis, which was implicated of contributing to the approximately 10-yr gap in the clinical manifestation of coronary heart disease (CHD) between men and women. In epidemiological and clinical studies, plasma levels of T had significant associations with the incidence or presence of CHD, which, however, were inverse in men and positive in women (1, 2, 3). Moreover, hypoandrogenemia in men and hyperandrogenemia in women are confounded with various metabolic disorders, including obesity, insulin resistance, dyslipidemia, and impaired fibrinolysis (3). Finally, case-control studies are limited by the problem that chronic illnesses, including CHD, as a stressful condition modulate serum levels of T (4). Few data are available from interventional studies: abuse of anabolic androgens has been held responsible for premature myocardial infarction in some athletes (5, 6); the contrary was observed when application of T to male CHD patients reduced clinical, electrocardiographic, and angiographic signs of coronary ischemia (1, 3, 7, 8, 9). In fact, T exerts both beneficial and adverse effects on cardiovascular risk factors by decreasing serum levels of lipoprotein(a), fibrinogen, and high density lipoprotein (HDL) cholesterol (1, 3). Likewise, conflicting data have been reported on the effect of T on vascular functions. Androgen deprivation in men was found to improve endothelial function (10, 11), and high dose application of androgens had detrimental effects in transsexual women (12); discrepantly, acute intravascular administration of T at very high dosages improved coronary artery relaxation and flow-mediated vasodilatation (FMD) of the brachial artery in men (13); low dose T treatment in postmenopausal women also ameliorated endothelial functions (14). Animal studies suggest that T regulates vasoreactivity by endothelium-dependent and -independent mechanisms, but are contradictory as well (15, 16, 17, 18, 19, 20). The genomic effects of T are exerted via activation of the AR, which regulates the transcription of target genes. A variable number of CAG repeats in exon 1, which encodes for glutamine residues in the amino-terminal domain of the AR and which normally ranges between 9–35 (21, 22), is inversely associated with the transcriptional response to T (23, 24). As the clinical consequence, the number of CAG repeats was shown to be associated with the incidence of prostate cancer (21, 22, 25, 26), benign prostatic hyperplasia (27, 28), and impaired spermatogenesis (29, 30, 31, 32). Furthermore, abnormal expansion of the CAG repeat length leads to Kennedy’s disease, which is accompanied by morphological hypoandrogenic traits (33, 34, 35).
In this study of healthy males, aged 20–50 yr, we addressed the question of whether the CAG repeat polymorphism in the AR gene influences cardiovascular risk factors and endothelial functions that may be impaired before the clinical onset of CHD (36, 37, 38, 39, 40).
Subjects and Methods
Besides the assessment of lipid profiles, life-style factors, body composition, and sexual hormones, we determined the CAG repeat polymorphism in the AR and investigated endothelial functions as putative early marker of vascular disease by noninvasively measuring the FMD of the brachial artery, a method previously demonstrated to be associated with coronary endothelial function and cardiovascular risk factors (38, 41, 42, 43, 44, 45, 46, 47).
Subjects
Healthy male Caucasians, aged 20–50 yr, were recruited by local newspaper advertisements that asked for volunteers willing to participate in a 1-term clinical study including the assessment of lipids, body fat content, and sexual hormones. They were informed that a genetic polymorphism was also to be investigated. They received a payment of 20 German marks and were all interested in obtaining the results. The study was approved by the ethics committee of the University and the State Medical Board (Munster, Germany; no. 0VIINie1). All volunteers gave written informed consent. After exclusion of previous androgen use, atherosclerosis, diabetes mellitus, arterial hypertension, dyslipoproteinemia, medication of any kind, drug abuse, a possible state of androgen deficiency (total serum T <12 nmol/liter or free T <250 pmol/liter), alcohol intake of more than 40 g/d, and renal or hepatic illness by history, physical examination, and serum/blood analysis, 110 men were eligible to participate in the study. Eight men were excluded for taking medication for arterial hypertension, 3 were excluded for use of cholesterol-lowering drugs, 2 were excluded for extensive consumption of alcohol, and 1 was excluded for previously diagnosed and treated diabetes mellitus type 1. No exclusion was necessary because of abnormal laboratory findings or a physical exam revealing pathological entities of any kind. Habitual cigarette smoking, alcohol consumption (grams per d), body weight, body height, and body mass index were assessed. Physical activity was expressed as the amount of strength and/or endurance training in hours per wk, resulting in an overall score of 1 (none) to 6 (>9 h/wk). This information was obtained by a standardized interview [retesting interobserver coefficient of variation (CV) in 18 subjects after 3 months was 8.5%]. All examinations and blood sampling were performed between 0800–1000 h after an overnight fast, including abstinence from caffeine-based drinks for 12 h. The clinical part of the study was completed within 4 wk during the summer.
Vascular ultrasound
Doppler ultrasound was used to assess the vascular reactivity of the brachial artery. Endothelium-dependent vasodilatation was induced by hyperemia, which triggers the release of nitric oxide from endothelial cells (48). For the assessment of endothelium-independent vasodilatation, the endothelium was bypassed by the exogenous application of glycerol trinitrate (GTN) (49). The method of assessing endothelial functions noninvasively was previously validated in studies of atherosclerosis (38, 43, 50) and is suitable for detecting the influence of androgens on the vascular endothelium (10, 11, 12, 13, 14).
Before the start of the examination the subjects rested in a room with a temperature of 20-24 C for 10–15 min. Subjects were investigated in the supine position. A high resolution ultrasonography 7.5-MHz linear phased array ultrasound transducer (ultrasound scanner type 2002 ADI, B-K Medical, Gentofte, Denmark) was used to image the dominant arm brachial artery longitudinally just above the antecubital fossa. The artery was identified by a pulsed Doppler signal at a 70° angle to the vessel with the range gate (1.5 mm) in the center of the artery. Additionally, color-coded duplex sonography was used. B-mode ultrasound images were used for measurements, the transmit zone was set to the depth of the near wall, and gain settings were not changed during the study. Digitalized motion sequences were saved for analysis. Arterial diameter was assessed over a 1-cm straight segment by measuring the distance from the anterior to the posterior wall (m-line, the interface between media and adventitia) at maximal resolution using the implemented software for distance measurements. After baseline images were obtained, a blood pressure cuff was placed over the ipsilateral upper arm just above the transducer, inflated for 4 min at 180 mm Hg, then suddenly deflated. Images of the flow-mediated dilator response were obtained 1 min after cuff release (maximal arterial dilatation). The brachial artery diameter was then allowed to return to normal (8 min). New baseline images were recorded, then 0.4 mg sublingual GTN was administered. Images from endothelial-independent vasodilation were obtained 3 min after application. The vessel diameter was assessed during maximal and minimal blood flow, as indicated by the color-coded pulse wave of three cardiac cycles at each time point; respective values were then averaged. This method captures the pulse-dependent maximum and minimum changes in vessel diameter. Body size (and, hence, distance from the aortic valve to the location of diameter assessment) does not influence the results as might be the case in electrocardiogram-triggered measurements. Flow-mediated and GTN-induced vasodilatation were calculated as the percent change in diameter compared with baseline. All scans were performed by one investigator who was blinded with respect to the subjects’ smoking habits, DNA analysis, or levels of lipids and sexual hormones. Respective intraobserver variability for repeated measurements of the vessel diameter is 1.6%. When reactive hyperemia studies were performed on 2 separate d, the intraobserver CV for FMD was 2.6% (based on 19 subjects).
Sexual hormones
Serum T levels were measured with a commercial ELISA kit (DRG Instruments GmbH, Marburg, Germany); serum levels of LH, FSH, PRL, prostate-specific antigen, SHBG, and E2 were measured with highly specific time-resolved fluoroimmunoassays (Autodelfia, Freiburg, Germany). The mean intraassay CV was below 5%; the mean interassay CV was below 10%. Levels of free T were calculated from levels of SHBG and total serum T according to the law of mass action, using 3.6 x 104 liter/mol as the association constant of T with albumin and 1 x 109 liter/mol with SHBG. Calculation with this method yields highly reliable values of levels of free T (51).
Biochemical analyses
A Hitachi 917 autoanalyzer was used for the quantification of serum concentrations of triglycerides and cholesterol with enzymatic tests, of HDL cholesterol with a homogenous assay, and of apolipoprotein A-I (apoA-I) with and lipoprotein(a) with (latex-enhanced) turbidimetric immunoassays (Hitachi/Roche, Mannheim, Germany). Imprecision was below 5%. Low density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula (52).
Plasma concentrations of soluble E-selectin (sE-selectin) and soluble vascular cell adhesion molecule 1 (sVCAM-1) were determined in duplicate by the use of enzyme immunoassays from Bender Medsystems Diagnostics GmbH (Vienna, Austria). The interassay CV was below 10%.
Determination of the number of CAG repeats within exon 1 of the AR gene
DNA was isolated from EDTA blood samples using the Nucleon Kit (Amersham Pharmacia Biotech, Freiburg, Germany). A fragment of exon 1 of the AR was amplified by PCR. Each reaction sample (25 µl) contained 100–500 ng genomic DNA, 20 pmol AR exon 1 for primer (5'-GCCTGTTGAACTCTTCTGAGC-3'), 20 pmol AR exon 1-rev primer [5'-CGATGGGCTTGGGGAGAACCATCCTCA-3', IRD (infrared dye)-800 labeled], reaction buffer [10 nmol/liter Tris-HCl (pH 8.3), 50 nmol/liter KCl, 0.01% gelatin, 2 nmol/liter MgCl2, and 0.2 mmol/liter deoxy-NTPs], and 2 U Taq polymerase (Promega Corp., Heidelberg, Germany). Denaturation at 94 C for 50 sec was followed by annealing at 58 C for 40 sec and an extension step at 72 C for 1 min. After initial incubation at 94 C for 2 min, PCR was performed for 35 cycles, with a final extension step at 72 C for 10 min. PCR products were tested by 2% agarose gel electrophoresis. The fluorescent PCR products (1–2 µl) were diluted with 2 µl loading dye fluorescent buffer sample (Amersham Pharmacia Biotech), and the total volume was adjusted to 5 µl using aqua dest. The samples were heated to 70 C for 1 min, then chilled on ice, and 1–2 µl were loaded onto a 6% denaturing sequencing gel. Samples were electrophoresed (Licor 4200, LiCor, Inc., Lincoln, NE) at 1500 V for 8 h. The number of CAG repeats were calculated by comparing the detected PCR fragment to sequencing reactions, which were run in parallel to the samples and served as molecular size markers. For example, a fragment with 372 bp contains 21 CAG repeats. In addition, PCR products with known numbers of CAG repeats (15, 21, and 30 CAG repeats, as determined by cloning and sequencing of corresponding AR’s exon 1 fragments) were assessed during each determination as well and were used as internal standards for the calculation. By this, migration aberrations due to changes in the electrophoretic properties, which could result in incorrect repeat calculations, were excluded. One gel showing irregular bands was discarded. Determination of CAG number was repeated twice on two separate gel runs. Discrepancies were not observed. Eighteen random samples were cloned and sequenced to confirm the validity of the measurement method being used.
Bioimpedance measurements
Body fat content was assessed by bioimpedance measurement using a B.I.A 2000-M multifrequency body composition analyzer (Data Input, Inc., Frankfurt/Main, Germany). A multifrequent alternating current (1, 5, 50, or 100 kHz, respectively) was used to eliminate variations in extra- and intracellular water contents. This method is more accurate than a single frequency approach (53). The same apparatus was used throughout, following the instructions given by the manufacturer. The patients were examined in a supine position after voiding. Total body water (TBW) was calculated from the measured impedance using the following formula: TBW = height (2)/impedance x 0.585 + 1.825 (54). Fat-free mass (FFM) was then calculated from the TBW by assuming 73.2% hydration of FFM: FFM = TBW/0.732 (55). Body fat mass was calculated using a two-compartment model: body weight = FFM + BFM. In our institute, the intraobserver CV is 2.34%; the interobserver CV is 6.77% (based on measurements by 3 investigators in 15 subjects). The measurements were performed by one investigator.
Statistics
All variables were checked for normal distribution by the Kolmogorov-Smirnov one-sample test for goodness of fit. When necessary, analysis was performed logarithmically or, for percentage values, on arcsine-transformed data. Basic correlations of the number of CAG repeats with parameters of interest were calculated after adjustment of data for age and body fat content. To investigate the simple influence of cigarette smoking on FMD, a two-tailed t test for unpaired samples was applied. To study the influence of T and the AR polymorphism on lipid profiles, FMD, and GTN-induced vasodilatation, the respective parameter was introduced as the dependent variable into a stepwise multiple regression model. The number of CAG repeats; levels of free T and E2, and other parameters of possible influence were entered as controlling variables. For lipid profiles, the controlling variables were body fat content, log age, physical activity, log alcohol consumption, and cigarette smoking; these controlling variables were applied for vascular parameters as well. Additionally, levels of LDL cholesterol and the baseline diameter of the brachial artery (showing a significant negative correlation with FMD in previous studies (38, 47) were entered. Computations were performed using the statistical software package SPSS (release 9.0.1, SPSS, Inc., Chicago, IL). Unless otherwise stated, results are given as the mean ± SD in tables and figures. A two-sided P < 0.05 was considered significant. Levels of statistical significance are shown in the figures as asterisks (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Results
General data
The range and distribution of the number of CAG repeats are
displayed in Fig. 1
; data for other
variables are given in Table 1. The
number of CAG repeats was significantly positively correlated with
levels of LH, as described previously (56) (Table 2). The AR polymorphism had no
significant association with serum levels of free T (Table 2). The
number of CAG repeats showed a significant positive basic correlation
with FMD, GTN-induced vasodilatation, and HDL cholesterol levels as
well as a slight negative correlation with serum levels of
triglycerides (Table 2). Of 110 participating men, 66 were nonsmokers,
and 44 were habitual smokers (>5 cigarettes/d). FMD was lower in
smokers than in nonsmokers (13.54 ± 6.27% and 9.26 ±
5.89%; P < 0.001, by two-tailed unpaired t
test).
|
|
|
By stepwise multiple regression analysis, the number of CAG
repeats showed a positive and highly significant correlation with serum
levels of HDL cholesterol (Table 3),
which is independent of body fat content and levels of free T (both
negative association; Table 3). The AR polymorphism accounted for
14.0% of the total variance in HDL cholesterol (partial r = 0.44;
P < 0.001; Fig. 2).
Figure 3 displays levels of HDL
cholesterol according to the quartiles of the CAG repeat distribution.
The HDL cholesterol levels of men within the lowest quartile of CAG
repeat numbers were significantly lower (mean ±
SD, 1.722 ± 0.29 mmol/liter) than the HDL
cholesterol levels of men within the highest quartile of CAG repeat
numbers (2.024 ± 0.41 mmol/liter; P < 0.01). In
addition, stepwise multiple regression showed the CAG repeat
polymorphism to be positively associated with serum levels of apoA-I,
which is the main protein component of HDL (ß = 0.239;
P = 0.012). This observation was independent of body
fat content (ß = -0.201; P = 0.033) and levels
of free T (ß = -0.175; P = 0.070). The
association between the number of CAG repeats and serum levels of
triglycerides just missed the level of statistical significance (Table 4). Levels of LDL cholesterol were best
predicted by a multiple regression model including body fat content
(ß = 0.323; P < 0.001), cigarette smoking
(ß = 0.320; P = 0.001), serum levels of E2
(ß = -0.369; P < 0.001), and log alcohol
consumption (ß = -1.99; P = 0.031; total
r2 = 0.353; total P <
0.001).
|
|
|
|
Upon stepwise multiple regression analysis the number of CAG
repeats model had a positive and highly significant association with
FMD, which is a measure of endothelial function (Table 5). This association was independent of
cigarette smoking and serum levels of LDL cholesterol and free T, which
also were correlated with FMD (Table 5). The AR polymorphism accounted
for 12.9% of the total variance (partial r = 0.37;
P < 0.001; Fig. 4).
These results were corroborated with high significance when only
nonsmoking individuals were introduced into the regression model.
Replacement of body fat content by body mass index also confirmed
results (data not given). GTN-induced and, hence,
endothelium-independent vasodilatation was also significantly and
positively correlated with the number of CAG repeats (ß = 0.181;
P = 0.049). Negative predictors were cigarette smoking
(ß = -0.191; P = 0.036) and the baseline
diameter of the brachial artery (ß = -0.252; P
= 0.007).
|
|
Discussion
The variable number of CAG repeats in exon 1, which encodes a polyglutamine tract in the amino-terminal domain of the AR, influences transcriptional activity and thereby the response of prostate and testes to T. In this study we extended these observations to nongonadal tissues. The lower the number of CAG repeats, the lower the serum levels of HDL cholesterol and apoA-I and the less extensive was FMD of the brachial artery. This association is also valid with regard to endothelium-independent vasodilatation induced by GTN. Physical activity did not have an influence on these parameters in our investigation. It is debatable whether this could be due to the nature of an ad hoc categorization, although it has a good reproducibility (see Subjects and Methods).
As AR variants with a low number of glutamine residues are more responsive to T than AR variants with a long polyglutamine stretch, our findings are in good agreement with the well known HDL-lowering effect of T. This phenomenon and our corresponding results underline that pivotal genes of HDL metabolism are transcriptionally regulated by the AR. Key candidates are hepatic lipase and the scavenger receptor B1, which are both importantly involved in the hepatic removal of HDL lipids (57). Twin studies suggest that 30–50% of the interindividual variation in HDL cholesterol is explained by genetic variation. However, little is known about the molecular basis of this variation. Some rare defects in the genes of apoA-I, lecithin cholesterol acyltransferase, and the ATP-binding cassette transporter A1 are the molecular basis of familial HDL deficiency syndromes, but do not contribute much to the variation in HDL cholesterol on the population level (57). Only polymorphisms in the genes of the cholesteryl ester transfer protein, hepatic lipase, and lipoprotein lipase contribute to a similar degree to the variation in HDL cholesterol at the population level as the CAG repeat polymorphism in the AR gene (58, 59, 60).
Previous data on the effect of T on the endothelium are complex and
controversial. T was shown to induce and inhibit vasodilatation by
endothelium-dependent and endothelium-independent mechanisms by genomic
and nongenomic effects (17, 61). Vascular effects induced
by T could be partly mediated via local aromatization to E2, but
although aromatase has been identified in vascular smooth muscle
cells, it could not be demonstrated in endothelial cells
(62). Furthermore, T effects could not be blocked by E
antagonists in previous studies (17). The positive
correlation between the number of CAG repeats in the AR gene and the
flow-induced vasodilatation we describe provides strong evidence that T
regulates vascular reactivity by genomic (i.e. AR-dependent)
and endothelium-dependent effects. In addition, the association of the
CAG repeat polymorphism with glyceroltrinitrate-induced vasodilatation
points to the regulation of endothelium-independent vasodilation by
genomic effects of T. In agreement with our findings, AR have been
localized in endothelial and vascular smooth muscle cells
(63, 64, 65). Two different, independent, T-induced effects on
the vessel can be assumed (61). The endothelium-dependent
pathway is likely to be represented by activation of endothelial nitric
oxide synthetase, as T effects can be suppressed by pretreatment with
n-
-nitro-L-arginine methyl ester to
block NO synthesis (17). A direct effect on vascular
smooth muscle cells is likely to be mediated via ATP-sensitive
potassium channels, as vascular T effects can be attenuated by the
potassium channel blocker glibenclamide (17). This pathway
seems to gain relevance when high concentrations of T are involved
(9, 13). These results are consistent with our findings
concerning T-mediated influences on endothelium-dependent and
-independent vasodilatation.
Transmigration of leukocytes into the arterial wall is a critical step in the development of acute and chronic inflammatory lesions in the artery and hence in the pathogenesis of atherosclerosis. This process is mediated by selectins such as E-selectins and subsequently by irreversible binding to adhesion molecules such as VCAM-1. Although VCAM-1 expression was previously reported to be regulated by T (66), we did not find any association of the CAG repeat polymorphism with serum levels of sVCAM-1. Shedding of selectins and adhesion molecules from the surface of the endothelium and the appearance of soluble isoforms in plasma (e.g. sE-selectin and sVCAM-1) is known to occur after endothelial injury (67). Thus, the lack of association does not contradict a regulatory effect of T on the expression of adhesion molecules, but mitigates the possibility that the association of the CAG repeat polymorphism with endothelial vasoreactivity is secondary to vascular injury.
In conclusion, we demonstrate in a population of healthy men not taking medication of any kind that the CAG repeat sequence polymorphism in the AR gene modulates the metabolic and cardiovascular effects of T. In consequence, a low number of CAG repeats represents a higher risk for reduced endothelial response to ischemia and lower levels of HDL cholesterol. Our results could explain the finding of significantly lower FMD in African Americans compared with Caucasian Americans (68), as the latter seem to have a significantly higher number of CAG repeats (21). Both low HDL cholesterol and endothelial dysfunction of the brachial artery are important risk factors for atherosclerosis (38, 47, 57). Therefore, a low number of CAG repeats in the AR gene appears to put men at increased risk for developing CHD.
Acknowledgments
We thank Nicole Terwort and Gabriele Klapdor for excellent technical assistance, and Susan Nieschlag, M.A., for language editing of the manuscript.
Footnotes
This work was supported by a grant from Interdisziplinäres Zentrum für klinische Forschung Münster (Project A3) and the Deutsche Forschungsgemeinschaft Confocal Research Group The Male Gamete: Production, Maturation, Function.
Abbreviations: apoA-I, Apolipoprotein A-I; CHD, coronary heart disease; CV, coefficient of variation; FFM, fat-free mass; FMD, flow-mediated vasodilatation; GTN, glycerol trinitrate; HDL, high density lipoprotein; LDL, low density lipoprotein; sE-selectin, soluble E-selectin; sVCAM-1, soluble vascular cell adhesion molecule 1; TBW, total body water.
Received February 22, 2001.
Accepted June 25, 2001.
References
This article has been cited by other articles:
 |
|
 |
|
  B. Kornmann, E. Nieschlag, M. Zitzmann, J. Gromoll, M. Simoni, and S. Von Eckardstein Body Fat Content and Testosterone Pharmacokinetics Determine Gonadotropin Suppression After Intramuscular Injections of Testosterone Preparations in Normal Men J Androl, September 1, 2009; 30(5): 602 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. T. Huhtaniemi, S. R. Pye, K. L. Limer, W. Thomson, T. W. O'Neill, H. Platt, D. Payne, S. L. John, M. Jiang, S. Boonen, et al. Increased Estrogen Rather Than Decreased Androgen Action Is Associated with Longer Androgen Receptor CAG Repeats J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 277 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R D Stanworth, D Kapoor, K S Channer, and T H Jones Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes Eur. J. Endocrinol., December 1, 2008; 159(6): 739 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Rexrode, P. M. Ridker, H. H. Hegener, J. E. Buring, J. E. Manson, and R. Y.L. Zee Genetic Variation of the Androgen Receptor and Risk of Myocardial Infarction and Ischemic Stroke in Women Stroke, May 1, 2008; 39(5): 1590 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nantermet, S.-i. Harada, Y. Liu, S. Cheng, C. Johnson, Y. Yu, D. Kimme, D. Holder, P. Hodor, R. Phillips, et al. Gene Expression Analyses in Cynomolgus Monkeys Provides Mechanistic Insight into High-Density Lipoprotein-Cholesterol Reduction by Androgens in Primates Endocrinology, April 1, 2008; 149(4): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Crabbe, V. Bogaert, D. De Bacquer, S. Goemaere, H. Zmierczak, and J. M. Kaufman Part of the Interindividual Variation in Serum Testosterone Levels in Healthy Men Reflects Differences in Androgen Sensitivity and Feedback Set Point: Contribution of the Androgen Receptor Polyglutamine Tract Polymorphism J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3604 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mohlig, A. Jurgens, J. Spranger, K. Hoffmann, M. O Weickert, H. W Schlosser, T. Schill, G. Brabant, A. Schuring, A. F H Pfeiffer, et al. The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur. J. Endocrinol., July 1, 2006; 155(1): 127 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Albertelli, A. Scheller, M. Brogley, and D. M. Robins Replacing the Mouse Androgen Receptor with Human Alleles Demonstrates Glutamine Tract Length-Dependent Effects on Physiology and Tumorigenesis in Mice Mol. Endocrinol., June 1, 2006; 20(6): 1248 - 1260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kaufman and A. Vermeulen The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications Endocr. Rev., October 1, 2005; 26(6): 833 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Zinn, P. Ramos, F. F. Elder, K. Kowal, C. Samango-Sprouse, and J. L. Ross Androgen Receptor CAGn Repeat Length Influences Phenotype of 47,XXY (Klinefelter) Syndrome J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5041 - 5046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hersberger, J. Muntwyler, H. Funke, J. Marti-Jaun, H. Schulte, G. Assmann, T. F. Luscher, and A. von Eckardstein The CAG Repeat Polymorphism in the Androgen Receptor Gene Is Associated with HDL-Cholesterol but Not with Coronary Atherosclerosis or Myocardial Infarction Clin. Chem., July 1, 2005; 51(7): 1110 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bots, J. Westerink, T. J. Rabelink, and E. J.P. de Koning Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response Eur. Heart J., February 2, 2005; 26(4): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Brum, P. M. Spritzer, F. Paris, M. A. Maturana, F. Audran, and C. Sultan Association Between Androgen Receptor Gene CAG Repeat Polymorphism and Plasma Testosterone Levels in Postmenopausal Women Reproductive Sciences, February 1, 2005; 12(2): 135 - 141. [Abstract] [PDF]
|
|
|
|
|
|
P. Y. Liu, R. C. Christian, M. Ruan, V. M. Miller, and L. A. Fitzpatrick Correlating Androgen and Estrogen Steroid Receptor Expression with Coronary Calcification and Atherosclerosis in Men without Known Coronary Artery Disease J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1041 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zitzmann, M. Depenbusch, J. Gromoll, and E. Nieschlag X-Chromosome Inactivation Patterns and Androgen Receptor Functionality Influence Phenotype and Social Characteristics as Well as Pharmacogenetics of Testosterone Therapy in Klinefelter Patients J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6208 - 6217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zitzmann, M. Depenbusch, J. Gromoll, and E. Nieschlag Prostate Volume and Growth in Testosterone-Substituted Hypogonadal Men Are Dependent on the CAG Repeat Polymorphism of the Androgen Receptor Gene: A Longitudinal Pharmacogenetic Study J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2049 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Woodhouse, S. Reisz-Porszasz, M. Javanbakht, T. W. Storer, M. Lee, H. Zerounian, and S. Bhasin Development of models to predict anabolic response to testosterone administration in healthy young men Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E1009 - E1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Richthoff, M. Spano, Y.L. Giwercman, B. Frohm, K. Jepson, J. Malm, S. Elzanaty, M. Stridsberg, and A. Giwercman The impact of testicular and accessory sex gland function on sperm chromatin integrity as assessed by the sperm chromatin structure assay (SCSA) Hum. Reprod., December 1, 2002; 17(12): 3162 - 3169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zitzmann, M. Brune, and E. Nieschlag Vascular Reactivity in Hypogonadal Men Is Reduced by Androgen Substitution J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5030 - 5037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dejager, H. Bry-Gauillard, E. Bruckert, B. Eymard, F. Salachas, E. LeGuern, S. Tardieu, R. Chadarevian, P. Giral, and G. Turpin A Comprehensive Endocrine Description of Kennedy's Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3893 - 3901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. von Eckardstein and E. Nieschlag Treatment of Male Hypogonadism With Testosterone Undecanoate Injected at Extended Intervals of 12 Weeks: A Phase II Study J Androl, May 1, 2002; 23(3): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
